Abeona Therapeutics Inc. (0H7R.L)
USD 5.88
(-2.0%)
USD 5.88
(-2.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 64 Million USD | -0.33% |
| 2022 | 64.21 Million USD | -19.31% |
| 2021 | 79.58 Million USD | -47.36% |
| 2020 | 151.19 Million USD | -32.31% |
| 2019 | 223.38 Million USD | 28.09% |
| 2018 | 174.39 Million USD | -2.44% |
| 2017 | 178.76 Million USD | 60.97% |
| 2016 | 111.05 Million USD | 38.73% |
| 2015 | 80.05 Million USD | 382.78% |
| 2014 | 16.58 Million USD | 2605.06% |
| 2013 | 613 Thousand USD | -64.57% |
| 2012 | 1.73 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 134 Million USD | 79.08% |
| 2024 Q1 | 74.82 Million USD | 16.92% |
| 2023 Q3 | 66.08 Million USD | 23.41% |
| 2023 Q1 | 53.34 Million USD | -16.93% |
| 2023 FY | 64 Million USD | -0.33% |
| 2023 Q2 | 53.55 Million USD | 0.38% |
| 2023 Q4 | 64 Million USD | -3.15% |
| 2022 Q1 | 55.17 Million USD | -30.68% |
| 2022 FY | 64.21 Million USD | -19.31% |
| 2022 Q4 | 64.21 Million USD | 65.67% |
| 2022 Q3 | 38.76 Million USD | -13.32% |
| 2022 Q2 | 44.71 Million USD | -18.95% |
| 2021 FY | 79.58 Million USD | -47.36% |
| 2021 Q1 | 141.43 Million USD | -6.46% |
| 2021 Q3 | 119.01 Million USD | -8.92% |
| 2021 Q4 | 79.58 Million USD | -33.13% |
| 2021 Q2 | 130.67 Million USD | -7.61% |
| 2020 Q1 | 175 Million USD | -21.66% |
| 2020 FY | 151.19 Million USD | -32.31% |
| 2020 Q2 | 164.37 Million USD | -6.07% |
| 2020 Q3 | 159.36 Million USD | -3.05% |
| 2020 Q4 | 151.19 Million USD | -5.12% |
| 2019 Q4 | 223.38 Million USD | 56.46% |
| 2019 FY | 223.38 Million USD | 28.09% |
| 2019 Q3 | 142.77 Million USD | -10.44% |
| 2019 Q2 | 159.41 Million USD | -4.05% |
| 2019 Q1 | 166.13 Million USD | -4.74% |
| 2018 Q2 | 166.69 Million USD | -5.1% |
| 2018 FY | 174.39 Million USD | -2.44% |
| 2018 Q1 | 175.65 Million USD | -1.74% |
| 2018 Q4 | 174.39 Million USD | 8.61% |
| 2018 Q3 | 160.57 Million USD | -3.67% |
| 2017 Q1 | 105.28 Million USD | -5.2% |
| 2017 FY | 178.76 Million USD | 60.97% |
| 2017 Q3 | 95.73 Million USD | -0.96% |
| 2017 Q4 | 178.76 Million USD | 86.74% |
| 2017 Q2 | 96.65 Million USD | -8.19% |
| 2016 Q2 | 74.15 Million USD | -4.22% |
| 2016 Q1 | 77.42 Million USD | -3.29% |
| 2016 FY | 111.05 Million USD | 38.73% |
| 2016 Q4 | 111.05 Million USD | 50.46% |
| 2016 Q3 | 73.81 Million USD | -0.46% |
| 2015 Q1 | 13.11 Million USD | -20.9% |
| 2015 FY | 80.05 Million USD | 382.78% |
| 2015 Q4 | 80.05 Million USD | -10.6% |
| 2015 Q3 | 89.54 Million USD | 16.41% |
| 2015 Q2 | 76.92 Million USD | 486.45% |
| 2014 Q1 | 478 Thousand USD | -22.02% |
| 2014 Q2 | 240 Thousand USD | -49.79% |
| 2014 Q3 | 280 Thousand USD | 16.67% |
| 2014 FY | 16.58 Million USD | 2605.06% |
| 2014 Q4 | 16.58 Million USD | 5822.14% |
| 2013 Q2 | 2.39 Million USD | 39.28% |
| 2013 Q4 | 613 Thousand USD | -43.86% |
| 2013 Q1 | 1.72 Million USD | -0.52% |
| 2013 Q3 | 1.09 Million USD | -54.44% |
| 2013 FY | 613 Thousand USD | -64.57% |
| 2012 FY | 1.73 Million USD | 0.0% |
| 2012 Q4 | 1.73 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Editas Medicine, Inc. | 499.15 Million USD | 87.178% |
| Dynavax Technologies Corporation | 997.09 Million USD | 93.581% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 95.458% |
| Perrigo Company plc | 10.8 Billion USD | 99.408% |
| Illumina, Inc. | 10.11 Billion USD | 99.367% |
| Thermo Fisher Scientific Inc. | 98.72 Billion USD | 99.935% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 91.798% |
| Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 99.921% |
| IQVIA Holdings Inc. | 26.68 Billion USD | 99.76% |
| Heron Therapeutics, Inc. | 222.5 Million USD | 71.236% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 99.807% |
| Unity Biotechnology, Inc. | 65.69 Million USD | 2.57% |
| Waters Corporation | 4.62 Billion USD | 98.617% |
| Biogen Inc. | 26.84 Billion USD | 99.762% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | 61.286% |
| Evolus, Inc. | 188.99 Million USD | 66.136% |
| Adicet Bio, Inc. | 207.29 Million USD | 69.125% |
| Cara Therapeutics, Inc. | 125.84 Million USD | 49.142% |
| bluebird bio, Inc. | 619.16 Million USD | 89.663% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | 68.9% |
| FibroGen, Inc. | 423.52 Million USD | 84.888% |
| Agilent Technologies, Inc. | 10.76 Billion USD | 99.405% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -126.376% |
| Homology Medicines, Inc. | 47.05 Million USD | -36.01% |
| Geron Corporation | 394.07 Million USD | 83.759% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 98.329% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 91.772% |
| Myriad Genetics, Inc. | 1.19 Billion USD | 94.661% |
| Viking Therapeutics, Inc. | 368.49 Million USD | 82.631% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 95.08% |
| Zoetis Inc. | 14.28 Billion USD | 99.552% |
| Mettler-Toledo International Inc. | 3.35 Billion USD | 98.093% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 99.065% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 99.718% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -14.393% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 97.86% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | 61.329% |
| Verastem, Inc. | 149.71 Million USD | 57.252% |
| Nektar Therapeutics | 398.03 Million USD | 83.92% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | 89.12% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | 67.578% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 98.04% |
| OPKO Health, Inc. | 2.01 Billion USD | 96.819% |
| Exelixis, Inc. | 2.94 Billion USD | 97.825% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 98.032% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | 89.702% |
| Anavex Life Sciences Corp. | 154.38 Million USD | 58.544% |
| uniQure N.V. | 831.68 Million USD | 92.305% |
| Imunon, Inc. | 21.91 Million USD | -192.006% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 93.9% |
| Insmed Incorporated | 1.32 Billion USD | 95.187% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 96.307% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 93.17% |
| TG Therapeutics, Inc. | 329.58 Million USD | 80.581% |
| Incyte Corporation | 6.78 Billion USD | 99.056% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | 96.512% |